Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AACR, Abemaciclig, accomplished, acknowledgement, advocacy, analytical, Argentina, Belize, bioavailability, Bipartisan, black, blinded, Bolivia, box, Brazil, breast, British, carcinogenicity, CDK, Chile, China, Chinese, chosen, CMS, Colombia, copy, Costa, CRADA, Cuba, cyber, DC, dear, disgorgement, Dominican, driver, dual, Ecuador, El, embarking, enasidenib, ester, forthcoming, France, French, genetic, germline, grace, Guatemala, Guiana, Haiti, HanX, HCW, hearing, hematopoietic, highlighted, hrs, Ibrance, IEC, incorrect, inhibitor, inhibitory, internationally, invoice, ivosidenib, JMML, junior, Juvenile, Laidlaw, lend, leukemic, Mexico, molecularly, multifaceted, NCI, Nicaragua, NIH, nonoccurrence, novelty, OS, overcome, Palbociclib, Panama, Paraguay, parity, PCAOB, penny, Peru, Pfizer, Pint, Pivotal, plausible, potency, predefined, Preliminarily, pro, prominent, provisional, purity, qualitative, quantitative, rank, ranking, RASopathiesNet, RASopathy, rata, RBC, ready, Reauthorization, recapitalization, reclassification, regime, reorganization, Republic, resubmit, Ribociclib, Rica, salt, Salvador, SAP, screening, Sock, South, Src, statutorily, strength, stricter, subfamily, Suriname, technique, trail, transduction, transfusion, undercut, underwritten, unexpired, unissued, unrepatriated, unreserved, Uruguay, USA, Venezuela, VHR, Wainwright, Washington, xenograft
Filing tables
Filing exhibits
Related press release
Associated TRAW transcripts
TRAW similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 333-191161, Form S-8 No. 333-194228, Form S-8 No. 333-204210, Form S-8 No. 333-210694, Form S-8 No. 333-215575, Form S-8 No. 333-222400, Form S-3 No. 333-221684, Form S-1 No. 333-207533, Form S-1 No. 333-211769 and Form S-1 No. 333-222374) of our report dated March 16, 2018, with respect to the consolidated financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2017.
/s/ Ernst & Young LLP | ||
Philadelphia, Pennsylvania March 16, 2018 |
Consent of Independent Registered Public Accounting Firm